Acromegaly - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘Acromegaly - Pipeline Review, H1 2016', provides an overview of the Acromegaly pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acromegaly, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acromegaly - The report reviews pipeline therapeutics for Acromegaly by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acromegaly therapeutics and enlists all their major and minor projects - The report assesses Acromegaly therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acromegaly Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acromegaly - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acromegaly Overview 9 Therapeutics Development 10 Pipeline Products for Acromegaly - Overview 10 Pipeline Products for Acromegaly - Comparative Analysis 11 Acromegaly - Therapeutics under Development by Companies 12 Acromegaly - Therapeutics under Investigation by Universities/Institutes 13 Acromegaly - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Acromegaly - Products under Development by Companies 17 Acromegaly - Products under Investigation by Universities/Institutes 18 Acromegaly - Companies Involved in Therapeutics Development 19 Aegis Therapeutics, LLC 19 Antisense Therapeutics Limited 20 Chiasma, Inc. 21 Crinetics Pharmaceuticals, Inc. 22 DexTech Medical AB 23 Foresee Pharmaceuticals, LLC 24 Glide Pharmaceutical Technologies Limited 25 Ionis Pharmaceuticals, Inc. 26 Ipsen S.A. 27 Italfarmaco S.p.A. 28 Novartis AG 29 Peptron, Inc. 30 Sompharmaceuticals S.A. 31 Strongbridge Biopharma plc 32 Acromegaly - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Target 34 Assessment by Mechanism of Action 36 Assessment by Route of Administration 38 Assessment by Molecule Type 40 Drug Profiles 42 ATL-1103 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 BIM-23A758 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 COR-005 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 FP-002 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 G-02113 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ISIS-GHRLRx - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 ITF-2984 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 L-779976 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 octreotide acetate - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 octreotide acetate - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 octreotide acetate - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 octreotide acetate long acting - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 octreotide acetate SR - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 octreotide SR - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 pasireotide ER - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Somadex - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 SXN-101742 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 SXN-101959 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Acromegaly - Recent Pipeline Updates 68 Acromegaly - Dormant Projects 79 Acromegaly - Discontinued Products 80 Acromegaly - Product Development Milestones 81 Featured News & Press Releases 81 Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference 81 Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced 81 Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly 82 Aug 10, 2015: ANP Licensing Partner for ATL1103 Cortendo Files Prospectus 83 Jun 15, 2015: Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly 83 Apr 16, 2015: ATL1103 - New European Patent Application Allowance 84 Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015 84 Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence 85 Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules 85 Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly 87 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Number of Products under Development for Acromegaly, H1 2016 10 Number of Products under Development for Acromegaly - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Acromegaly - Pipeline by Aegis Therapeutics, LLC, H1 2016 19 Acromegaly - Pipeline by Antisense Therapeutics Limited, H1 2016 20 Acromegaly - Pipeline by Chiasma, Inc., H1 2016 21 Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016 22 Acromegaly - Pipeline by DexTech Medical AB, H1 2016 23 Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 24 Acromegaly - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016 25 Acromegaly - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 26 Acromegaly - Pipeline by Ipsen S.A., H1 2016 27 Acromegaly - Pipeline by Italfarmaco S.p.A., H1 2016 28 Acromegaly - Pipeline by Novartis AG, H1 2016 29 Acromegaly - Pipeline by Peptron, Inc., H1 2016 30 Acromegaly - Pipeline by Sompharmaceuticals S.A., H1 2016 31 Acromegaly - Pipeline by Strongbridge Biopharma plc , H1 2016 32 Assessment by Monotherapy Products, H1 2016 33 Number of Products by Stage and Target, H1 2016 35 Number of Products by Stage and Mechanism of Action, H1 2016 37 Number of Products by Stage and Route of Administration, H1 2016 39 Number of Products by Stage and Molecule Type, H1 2016 41 Acromegaly Therapeutics - Recent Pipeline Updates, H1 2016 68 Acromegaly - Dormant Projects, H1 2016 79 Acromegaly - Discontinued Products, H1 2016 80
List of Figures
Number of Products under Development for Acromegaly, H1 2016 10 Number of Products under Development for Acromegaly - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 33 Number of Products by Targets, H1 2016 34 Number of Products by Stage and Targets, H1 2016 34 Number of Products by Mechanism of Actions, H1 2016 36 Number of Products by Stage and Mechanism of Actions, H1 2016 36 Number of Products by Routes of Administration, H1 2016 38 Number of Products by Stage and Routes of Administration, H1 2016 38 Number of Products by Molecule Types, H1 2016 40 Number of Products by Stage and Molecule Types, H1 2016 40
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.Read More...
North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption ratRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.